FSD Pharma announces appointment of Nathan Coyle, the company's corporate controller as its interim chief financial officer with immediate effect
FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) has announced the appointment of Nathan Coyle, the company’s corporate controller as its interim chief financial officer with immediate effect, following the departure of Donal Carroll.
The company noted that Coyle joined FSD Pharma as corporate controller in 2020 and has 15 years of executive business experience as a finance leader in both public and private roles. He was previously with Illinois Tool Works where he was a key player in restructuring the organization, shaping the growth and streamlining businesses within his industrial packaging segment.
READ: FSD Pharma in license agreement with Innovet Italia to develop FDA-approved drugs to treat gastrointestinal diseases in dogs and cats
After ITW, Coyle worked with a private organization implementing the same corporate strategies to maximize growth. He holds a Bachelor of Business Administration with honours from Brock University and is a Chartered Professional Accountant.
FSD Pharma Inc. is a publicly-traded holding company. FSD BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, ultra-micro PEA by down-regulating the cytokines to effectuate an anti-inflammatory response.
The company filed an IND with the US Food & Drug Administration (FDA) on August 28, 2020, which was approved on September 25, 2020, to initiate a phase 2 clinical trial for the use of FSD201 to treat coronavirus (COVID-19), the disease caused by the SARS-CoV-2 virus. The trial is currently underway and is expected to randomize 352 patients in a controlled, double-blind multicenter study.
Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. The company is focused on developing ultra-micro PEA for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.
Contact the author at [email protected]
Story by ProactiveInvestors
Source: http://www.proactiveinvestors.com/companies/news/948606/fsd-pharma-announces-appointment-of-nathan-coyle-the-company-s-corporate-controller-as-its-interim-chief-financial-officer-with-immediate-effect-948606.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).